Moreover, the mRNA levels of fibrosis markers, including αSMA and Col1α1, were decreased by SKO-001 (Fig. 7E), as revealed via immunostaining (Fig. 7D), which implies that SKO-001 may also have beneficial effects on liver fibrosis and cirrhosis. Here, COL1A1 is linked to Hepatic fibrosis.